BioCurex Presents Positive Results At International Oncology and Biomarkers Congress With Its RECAF(TM) Cancer Marker
RICHMOND, British Columbia, Sept. 29, 2009 -- Whispering Oaks International, Inc., d/b/a Biocurex (OTCBB:BOCX), announced today that it is making two presentations at the annual meeting of the International Society of Oncology and Biomarkers (ISOBM) being held this week in Amsterdam, The Netherlands. BioCurex's presentations address its RECAF cancer market test in combination with other currently used cancer markers: CA-125 for ovarian cancer and CEA for colorectal cancer.
The company's data show that combining RECAF with CA-125 detected 83% of ovarian cancers and combining RECAF with CEA detected 92% of colorectal cancers, with no false positives in either study. False positives are the most common reasons that most cancer marker tests are not useful for general screening. By combing the results of RECAF with these other cancer markers, the false positive rate was completely eliminated.
In addition, when the method was applied to very early stages of ovarian cancer, where a very high percentage of patients can be treated effectively, the combination test was still able to detect 75% of the cancer cases.
Dr. Moro, the Company's Chief Executive Officer, stated: "This is an important step ahead because CA-125 and CEA have been around for decades and combining them with RECAF provides a solution to the main problem with screenings: namely eliminating false positives while still detecting cancer cases at a high rate."
For more information on cancer markers, visit:
http://www.cancer.gov/cancertopics/factsheet/Detection/tumor-markers
http://www.cancer.net/portal/site/patient/menuitem.169f5d85214941ccfd748f68ee37a01d/?vgnextoid=5662e195df06e010VgnVCM100000ed730ad1RCRD
For information about the ISOBM visit www.isobm.org
About BioCurex
BioCurex is a development stage diagnostics company focusing on development and commercialization of products for the early detection, diagnosis, and monitoring of recurrence of cancer. BioCurex has developed a blood test that can detect the presence of cancer in humans and companion animals using a new cancer marker named RECAF. To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Forward Looking Statement Disclaimer
This release contains a number of forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expresses or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties.
CONTACT:
Biocurex
Ricardo Moro
(604) 207-9150
www.biocurex.com
